Acer Therapeutics Inc.
DelistedCIK 1069308fmd_14ZHE5JSZ4C88ENQ5E839M4WSHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2004 to Sep 30, 2023, 60 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 0 | 1 | – |
| Net interest income | – | 0 | 0 | 0 | – | – | – | – | – | – |
| Research and development | 9 | 12 | 10 | 5 | 9 | 12 | 14 | 12 | 7 | 12 |
| Total operating expenses | – | – | – | 7 | 14 | 22 | 30 | 23 | 17 | 25 |
| Operating income | (12) | (15) | (12) | (7) | (14) | (22) | (30) | (23) | (16) | (25) |
| Interest expense | 2 | 0 | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | – | 0 | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | (0) | 0 | 0 | (0) | 1 | (2) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (17) | (15) | (12) | (7) | (14) | (21) | (29) | (23) | (15) | (26) |